

Vancomycin injection – New warning

- On September 28, 2017, the [FDA approved](#) an update to the *Warnings* section of the [vancomycin](#) injection drug label regarding hemorrhagic occlusive retinal vasculitis (HORV).
- Vancomycin is indicated for the following:
 - Treatment of serious or severe infections caused by susceptible strains of methicillin-resistant (beta-lactam-resistant) staphylococci.
 - For penicillin-allergic patients, for patients who cannot receive or who have failed to respond to other drugs, including the penicillins or cephalosporins, and for infections caused by vancomycin-susceptible organisms that are resistant to other antimicrobial drugs.
 - For initial therapy when methicillin-resistant staphylococci are suspected, but after susceptibility data are available, therapy should be adjusted accordingly.
- HORV, including permanent loss of vision, occurred in patients receiving intracameral or intravitreal administration of vancomycin during or after cataract surgery. The safety and efficacy of vancomycin administered by the intracameral or the intravitreal route have not been established by adequate and well controlled trials. Vancomycin is not indicated for prophylaxis of endophthalmitis.